GO
Loading...

Roche Holding AG

More

  • NEW YORK, July 10- A U.S. court on Thursday rejected an appeal by Taiwan- based AU Optronics Corp of the $500 million criminal fine the company was ordered to pay in 2012 after a conviction for price-fixing in the market for liquid crystal display panels. AU Optronics appealed it as excessive.

  • *EU shift to Avastin a threat to Novartis, Bayer profits. PARIS, July 8- French lawmakers voted on Tuesday to allow the use of Roche's cancer drug Avastin as a cheap alternative eye treatment, in a budget-minded move critics fear could put patients' health- and company profits- at risk.

  • "There's reason to think that the level of fines imposed on miscreants is not as high as it ought to be, given the harm that is done," said Bert Foer, president of the American Antitrust Institute, a group in Washington, D.C., that favors aggressive enforcement of competition laws. The institute asked the Sentencing Commission to reexamine fines a year ago.

  • LONDON, July 6- The drugs don't work- and neither does the market, when it comes to antibiotics. Totally resistant forms of the lung infection emerged in India just a few years ago and have now been detected worldwide.

  • INSIGHT-How to fix a broken market in antibiotics Sunday, 6 Jul 2014 | 4:59 AM ET

    LONDON, July 6- The drugs don't work- and neither does the market, when it comes to antibiotics. Totally resistant forms of the lung infection emerged in India just a few years ago and have now been detected worldwide.

  • NEW YORK, July 2- U.S. stock indexes were little changed on Wednesday, with the Dow industrials hovering just below 17,000, after the U.S. private sector created many more jobs than expected last month.

  • NEW YORK, July 2- U.S. stocks were set to rise slightly at the open on Wednesday, with the Dow industrials ready to pierce through 17,000, after the U.S. private sector created many more jobs than expected last month.

  • *Economist Jim O'Neill to head new antibiotics panel. LONDON, July 2- Prime Minister David Cameron called on Wednesday for global action to tackle the threat of drug-resistant superbugs and said Britain planned to take a leading role in finding ways to spur the development of new antibiotics.

  • Roche buying Seragon in US for up to $1.7 billion Wednesday, 2 Jul 2014 | 4:06 AM ET

    GENEVA— Roche Holding AG says its U.S.-based biotech company Genentech has agreed to acquire American biotechnology firm Seragon Pharmaceuticals, Inc. for up to $1.725 billion in cash and contingency payments.

  • UK's Cameron calls for global action on superbug threat Wednesday, 2 Jul 2014 | 4:06 AM ET

    *Economist Jim O'Neill to head new antibiotics panel. LONDON, July 2- Prime Minister David Cameron called on Wednesday for global action to tackle the threat of drug-resistant superbugs and said Britain planned to take a leading role in finding ways to spur the development of new antibiotics.

  • *Roche adds to breast cancer drug offering with Seragon. Roche is looking to bolster its offering of breast cancer drugs with the purchase. Since walking away from a $6.8 billion deal to buy U.S gene sequencing company Illumina in 2012 Roche has eschewed multi-billion deals and instead snapped up a couple of smaller diagnostic companies so far this year.

  • June 30- Allergan Inc said on Monday that the U.S. Food and Drug Administration would not approve its acute migraine aerosol treatment until certain concerns are addressed, but the agency approved a new use for its implantable eye drug, Ozurdex.

  • WASHINGTON/ MUMBAI, June 27- India's Ranbaxy Laboratories Ltd has received approval from the U.S. Food and Drug Administration to launch a cheaper copy of Novartis AG's blood pressure pill Diovan, bolstering its outlook after a raft of regulatory bans for poor production quality at its India facilities dented investor sentiment.

  • June 24- A late-stage trial testing Bristol-Myers Squibb Co's cancer immunotherapy nivolumab in advanced melanoma patients was halted early after it was determined that the drug was likely to prolong survival, the company said on Tuesday.

  • UPDATE 1-Ohr Pharma eye drug falls short in trial Tuesday, 24 Jun 2014 | 8:16 AM ET

    June 24- Ohr Pharmaceutical Inc said its experimental eye drop showed no significant benefit over a placebo in reducing the number of injections of another drug directly into the eye, but improved patients' visual clarity.

  • June 16- A drug approved to prevent rejection of transplanted kidneys significantly reduced relapses of multiple sclerosis in a late stage-trial sponsored by Biogen Idec and AbbVie Inc, but serious infections and potential liver toxicity continued to cloud the drug's future.

  • SHANGHAI, June 13- China's crackdown on corruption in the pharmaceutical sector has frightened foreign executives so much that some fear they could be jailed and have asked their lawyers if they should leave the country for six months.

  • A takeover bid that caused much consternation didn't even go through after AstraZeneca PLC said "no thanks" to Pfizer Inc. in April. The episode caused Eric Sappenfield, co-manager of the John Hancock Global Shareholder Yield Fund, to turn cautious on Pfizer, although he still owns some.

  • CNBC's Meg Tirrell and Daniel O'Day, Roche Holdings COO, discuss the latest developments in immunotherapy and treating bladder cancer.

  • What new GSK cancer deal shows about pharma market Monday, 2 Jun 2014 | 3:33 AM ET

    The announcement that GSK is planning to spend $350 million plus to get a slice of a U.K. biotech's cancer drugs has raised eyebrows.